ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Coronavirus

Fujifilm unit to launch new coronavirus testing kit

Camera company joins global giants to meet surging demand

Fujifilm Wako Pure Chemical's coronavirus kit includes a reagent used in polymerase chain reaction-based tests.

TOKYO -- Fujifilm Holdings is to launch a coronavirus testing kit that the Japanese company said would speed up results by two hours, joining a string of global pharma groups in responding to surging demand as the global pandemic widens.

The kit was developed by Fujifilm's Osaka-based subsidiary, Fujifilm Wako Pure Chemical, and will be sold to health laboratories and testing institutions from April 15, the company said on Friday.

The kit includes a reagent used in polymerase chain reaction (PCR) based tests. Conventional tests consisted of extracting ribonucleic acid (RNA) from saliva, mixing it with a reagent to convert to DNA using a container and then moving it to a separate container to duplicate the DNA. Fujifilm said its reagent can be used in both conversion and duplication, eliminating the need to change containers.

If used with kits from partner companies, the entire testing process can be 2-4 hours instead of the current 4-6 hours, it said. The kit can be used on existing testing machines.

Fujifilm shares rose 6% on Friday.

Fujifilm Wako Pure Chemical, a former unit of Takeda Pharmaceutical, was acquired by Fujifilm in 2017. It specializes in reagents but the company said it was the first time it had developed a kit for PCR-based tests.

Major testing kit producers like Switzerland's Roche are also ramping up production as COVID-19 cases rise globally. In Japan, Takara Bio and Toyobo produce testing kits.

A separate subsidiary of Fujifilm produces the anti-flu drug Avigan, which is being tested in clinical trials as a potential treatment for COVID-19.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more